ReviewFrontiers in medicine2026
Engineered exosome biomedical technologies for precision diagnosis and therapy in orthopedic diseases.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanoimmunomodulation for cartilage repair in osteoarthritis: reprogramming the inflammatory joint microenvironment.International journal of pharmaceutics: X · 2026Review
- Mammalian cell-derived extracellular vesicles remodel the immune-repair microenvironment in osteoarthritis: from pathological signal transmission to regenerative therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With population aging and sports-related injuries on the rise, the incidence of osteoarthritis, osteoporotic fractures, nonunion bone defects, and bone tumors continues to increase, while conventional pharmacologic and surgical interventions face limitations in target specificity, safety, and cost-effectiveness. Extracellular vesicles, particularly exosomes, are cell-derived nanoscale vesicles that can be engineered via surface ligand/peptide conjugation, membrane protein engineering, and nucleic acid or protein cargo loading to improve targeting, stability, and controlled release. These advances position engineered exosomes as promising platforms for the diagnosis and treatment of orthopedic disorders. Here, we review exosome architecture and biological properties, and systematically summarize extraction, purification, and engineering strategies, alongside their applications to osteoarthritis, osteoporosis, fracture healing, and bone malignancies. Reported therapeutic mechanisms include promotion of osteogenesis and angiogenesis, immunomodulation and anti-inflammatory effects, and regulation of autophagy and apoptosis. Nevertheless, significant barriers remain for clinical translation. To enable routine clinical use, future work should address product heterogeneity, scalable manufacturing, cargo stability, release kinetics, and long-term safety, supported by robust quality control and standardization. Finally, we adopt a technology-centric framework that maps engineering modalities to orthopedic indications and quantifiable performance metrics, outlining the review's methodological route and evidence synthesis approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.